Slide

Newsroom

Press Releases

Exciting things are happening at Aulos™ Bioscience. Here is the latest news about our company and pipeline.

October 9, 2024

Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

...

October 4, 2024

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

...

May 23, 2024

Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting

...

May 15, 2024

Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007

...

April 24, 2024

Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting

...

January 25, 2024

First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers

...

December 18, 2023

Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

...

November 3, 2023

New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

...

October 14, 2023

New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

...

October 4, 2023

Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

...